MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

Search

Emergent BioSolutions Inc

Abrir

SetorSaúde

9.31 2.42

Visão Geral

Variação de preço das ações

24h

Atual

Mín

9.02

Máximo

9.33

Indicadores-chave

By Trading Economics

Rendimento

-80M

-12M

Vendas

-81M

141M

P/E

Médio do Setor

3.399

35.739

Margem de lucro

-8.517

Funcionários

900

EBITDA

-131M

1.6M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+28.73% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

154M

477M

Abertura anterior

6.89

Fecho anterior

9.31

Sentimento de Notícias

By Acuity

7%

93%

5 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

Emergent BioSolutions Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

2 de out. de 2025, 23:30 UTC

Ações em Alta

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2 de out. de 2025, 21:21 UTC

Ganhos

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3 de out. de 2025, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2 de out. de 2025, 23:40 UTC

Conversa de Mercado

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2 de out. de 2025, 23:39 UTC

Conversa de Mercado

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2 de out. de 2025, 23:29 UTC

Aquisições, Fusões, Aquisições de Empresas

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2 de out. de 2025, 23:29 UTC

Aquisições, Fusões, Aquisições de Empresas

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2 de out. de 2025, 23:29 UTC

Aquisições, Fusões, Aquisições de Empresas

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2 de out. de 2025, 23:00 UTC

Conversa de Mercado

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2 de out. de 2025, 22:54 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Scales's JV Buyout Lauded by Bull -- Market Talk

2 de out. de 2025, 22:54 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Global Forex and Fixed Income Roundup: Market Talk

2 de out. de 2025, 22:46 UTC

Conversa de Mercado

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2 de out. de 2025, 22:46 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

2 de out. de 2025, 21:17 UTC

Aquisições, Fusões, Aquisições de Empresas

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2 de out. de 2025, 20:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Energy & Utilities Roundup: Market Talk

2 de out. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

2 de out. de 2025, 20:49 UTC

Aquisições, Fusões, Aquisições de Empresas

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2 de out. de 2025, 20:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2 de out. de 2025, 19:20 UTC

Conversa de Mercado

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2 de out. de 2025, 19:10 UTC

Conversa de Mercado

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2 de out. de 2025, 19:04 UTC

Conversa de Mercado

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2 de out. de 2025, 18:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2 de out. de 2025, 18:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2 de out. de 2025, 18:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2 de out. de 2025, 18:45 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2 de out. de 2025, 18:45 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2 de out. de 2025, 18:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2 de out. de 2025, 18:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2 de out. de 2025, 18:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2 de out. de 2025, 18:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Comparação entre Pares

Variação de preço

Emergent BioSolutions Inc Previsão

Preço-alvo

By TipRanks

28.73% parte superior

Previsão para 12 meses

Média 11.83 USD  28.73%

Máximo 15 USD

Mínimo 8.5 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para Emergent BioSolutions Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

3 ratings

2

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

4.95 / N/ASuporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

5 / 371 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Emergent BioSolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
help-icon Live chat